Notícias

Court strips shareholder case of class-action status

(Bloomberg) -- Lawyers for President Donald Trump and his sprawling business interests are heading to court this week in Florida for high-stakes hearings that follow a pair of major setbacks in their wave of multibillion-dollar lawsuits.Most Read from BloombergUS Strikes Iran in Escalating Campaign After Troops KilledThousands of Trucks Haul Iraq’s Oil Through Syria in Sign of Hormuz LegacyUS Strikes Iran to ‘Punish’ It for Attack That Killed 2 TroopsTrump Silent So Far on Iran Plans as US Death

On the latest episode of Equity, we debate whether Apple's lawsuit will cast over OpenAi's much-discussed plans to get into hardware and go public.

A parasite outbreak tied to Taylor Farms sends Walmart and Yum Brands shares lower while Sweetgreen rallies on relief.

(Bloomberg) -- Walmart Inc. said it has removed four bagged iceberg lettuce salad products manufactured by Taylor Farms as recalls tied to a cyclosporiasis outbreak expand. Most Read from BloombergFCC Near Rulings Against Disney Over ‘The View,’ TV LicensesTaylor Farms Pulls Mexican Lettuce as Parasite Cases RiseChip Stocks Slide Into Bear Market in AI Unwind: Markets WrapSpaceX Slump Wipes Out $1 Trillion in Market Value From PeakGoogle Gemini Launch Delayed as Tech Falls Short of Internal Goal

By Daniel Wiessner July 17 (Reuters) - A U.S. judge on Friday rejected a bid by 26 employees of Meta Platforms to block the tech giant from laying them off while they pursue claims that they were

Investing.com -- Apple Inc. and the US Justice Department are in early discussions to settle a 2024 antitrust lawsuit, Bloomberg reported Friday.

Apple ‌and ‌the U.S. Department ​of Justice are in ‌early ⁠discussions about settling ⁠a 2024 ​lawsuit ​that ​alleges the ‌iPhone maker violated antitrust laws, ‌Bloomberg ​News ​reported ​on ‌Friday. Reuters could not ​immediately ​verify the ​report. (Reporting ‌by Jaspreet ​Singh in ​Bengaluru)

(Bloomberg) -- Apple Inc. and the US Justice Department are in early discussions about settling a 2024 lawsuit that alleges the iPhone maker violated antitrust laws. Most Read from BloombergFCC Near Rulings Against Disney Over ‘The View,’ TV LicensesChip Stocks Poised for Bear Market in AI Unwind: Markets WrapGoogle Gemini Launch Delayed as Tech Falls Short of Internal GoalsChina’s Moonshot Unveils AI Model That Narrows Gap With US FirmsThailand Scraps Plan to End Visa-Free Entry for Indian Tour

NEW YORK, July 17 (Reuters) - A New York state judge dismissed a lawsuit by a former JPMorgan Chase banker who in graphic terms said his former supervisor coerced him into sex and demanded his

MSD has outpaced rivals to market the first PCSK9 inhibitor in pill form for patients with high cholesterol.

3M stock has more than doubled over the past three years, while current checks suggest the shares trade below an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach and also screen as undervalued on traditional earnings multiples. At the same time, a mixed broader valuation score and fresh legal action over PFAS chemicals mean the gap between price and estimated value is not a straightforward story. 3M has delivered a 103.6% return over the last three years, which puts...

There's a reason Costco will pretty much let you return any item at any time without a hassle. Costco has built its reputation on offering high-quality products at competitive prices, backed by strict supplier standards and careful product selection. The company knows its products have been ...

The daily medication is expected to be list-priced at $10.50 per pill. Here's what to know about Merck's new cholesterol drug Lipfendra.

Lipfendra, to be taken once a day, is designed to help lower cholesterol levels beyond what statins alone can achieve.

OpenAI’s struggles could cause the AI bubble to burst, bringing down with it much more than the company’s hardware division.

OpenAI says it sees no evidence supporting Apple's lawsuit over alleged trade-secret theft.

OpenAI plans a screen-free AI home device while Apple seeks an injunction that could delay its rollout.

OpenAI still plans a year-end device reveal, but Apple's lawsuit, ecosystem strength and rising component costs may complicate its hardware push.

July 15 () - Shares of Celcuity fell about 8% in premarket trading on Wednesday, as the delayed commercial launch ‌of its newly approved breast cancer drug and treatment-tolerability ‌concerns overshadowed the company's first U. Food and Drug Administration on ​Tuesday approved gedatolisib, branded as Revtorpyk, for certain patients with advanced breast cancer whose tumors do not carry a PIK3CA mutation.

Just one day after glowing reviews, a surprise revenue warning sent the stock into a tailspin and brought lawyers to the door.

Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s prescribing information surprised some analysts, too.

Alphabet unit Google on Wednesday urged Europe's top court to dismiss EU antitrust regulators' appeal ‌against a lower court ruling that scrapped a €1.49 billion ($1.7 billion) fine, saying ‌the regulators' arguments were flawed. The dispute reached the Court of Justice of the European Union ​after regulators appealed a 2024 General Court ruling that annulled the fine imposed on Google in 2019. The lower court cited errors in the European Commission's assessment of the case.

The primary reason for the 12-state lawsuit is that a Paramount-WBD combination would curb entertainment content and distribution, putting the TV/movie marketplace into fewer hands. What's the fallout?

The product is expected to be OpenAI’s first physical AI device and a crucial milestone as the company moves forward with its IPO plans.

The U.S. Department of Justice has expanded an antitrust investigation to include UnitedHealth Group's Claritev unit. The Claritev review is part of broader DOJ scrutiny of healthcare industry practices and market competition. This development adds a fresh layer of regulatory attention for UnitedHealth Group (NYSE:UNH) beyond routine oversight. UnitedHealth Group, one of the largest managed care and healthcare services companies in the U.S., spans insurance, care delivery, and data-driven...

OpenAI has issued another statement on the lawsuit, this time suggesting it lacks merit.

Apple seeks damages and other legal remedies that could slow OpenAI's device development and hiring.

OpenAI says it takes Apple’s complaint seriously but questions whether the allegations have any merit.

Gedatolisib, in-licensed from Pfizer in 2021, is Celcuity’s sole late-stage asset.